Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA)
Patients and clinicians should verify the current status with the MHRA and EMA, as the regulatory position may change
Patients without insurance coverage have several self-pay options
FDA Category 2 Bulk Drug Substances Nomination Review: BPC-157
Successful product development requires aligning raw material characteristics with the intended product vision
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
